As the January 1 implementation date approaches, here is a quick guide to the controversial new rebate model for the 340B Drug Pricing Program and the legal battle to stop it.

Michigan hospitals are systematically exploiting a program for low-income patients, according to a new report.

Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4 billion in 2024.

The AHA and several safety-net providers argue that an upcoming mandatory rebate pilot violates administrative law, imposes millions in costs, and threatens patient care in vulnerable communities.

Healthcare policy changes may increase uncompensated care, stressing hospitals and the 340B program, crucial for subsidizing low-income patient care. The 340B rebate model, starting in 2026, could ...

Too many hospitals take advantage of 340B, intended to make medications affordable for low-income patients. A New York ...

The 340B Drug Pricing Program was meant to help low-income patients, writes Rick Dowlearn, but it’s being used by hospitals ...

Hospital groups raise issues with 340B rebate pilot program citing cash flow, administrative costs, and unclear rebate denials risks.

HHS on March 17 filed a brief in a D.C. federal court supporting the agency's 340B program that provides discounted drugs to hospitals and clinics that primarily serve poor and underinsured patients.

St. Mary's in Lewiston is a plaintiff in the suit, which targets a pilot program introduced by the Trump administration.

The 340B drug discount program would work better if the money followed the patient rather than going directly to hospitals, Anthony DiGiorgio, DO, MHA, said Monday at an event on 340B sponsored by the ...

An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug ...